Steven brings nearly 20 years of experience building and leading world-class, integrated, translational, value-based health care systems and transformational biotechnology companies. He currently serves as managing director of Healthcare Ventures at Ziff Capital Partners and was previously chair of the board of directors at Spark Therapeutics (acquired by Roche in 2019). In his role at Ziff Capital Partners, Dr. Altschuler co-leads the firm’s efforts toward investing in, and facilitating the start-up and development of, companies with potentially transformative technologies that emphasize cellular and molecular approaches to human disease. He previously co-founded Spark Therapeutics to develop and commercialize the preclinical and clinical gene therapy programs advanced at the Children’s Hospital of Philadelphia (CHOP) and other institutions. He served as Spark’s board chair from its founding through its acquisition in 2019, which included leading the company through a successful transition to a public company and the launch of an approved commercial product, which was the first gene therapy for an inherited disease approved by the U.S. Food and Drug Administration and European Medicines Agency. Dr. Altschuler formerly held chief executive positions at CHOP and University of Miami Health System. He is chairman of the board of directors of 89bio and a member of the board of directors of WW (formerly Weight Watchers International), AsclepiX Therapeutics, ImVaX and Platelet Biogenesis. He is also an independent trustee of the Brigham and Women’s Physician Organization at Mass General Brigham.

Dr. Altschuler holds a B.A. in mathematics and an M.D. from Case Western Reserve University.

Joanne is currently chief operations officer at Boston Pharmaceuticals. Prior to joining Boston Pharmaceuticals, Joanne was the executive vice president of pharmaceutical development and operations and a member of the executive committee at Celgene. Prior to Celgene, Joanne was senior vice president of pharmaceutical development at Shire from 2012 to 2016. Before Shire, she held various leadership roles in Abbott’s global pharmaceutical operations and was the site head of Abbott Vascular Instruments GmbH. Earlier in her career, Joanne held positions in process development at Genentech and Amgen.

Joanne holds a B.A. from Lewis and Clark College and a Ph.D. from the University of Oregon Medical School.

John has had an extensive career as a clinician, researcher and drug development executive, bringing industry-leading expertise in advancing novel therapies through research and development and treating patients in need. Most recently, he served as executive vice president of research and development for Portola Pharmaceuticals, where he worked as the lead executive officer for all R&D activities. Prior to joining Portola, John served as chief executive officer at 3-V Biosciences and as president of the Research Institute at Schering-Plough Biopharma, where he helped progress eight therapeutic candidates into development. He began his biopharmaceutical career at Genentech, where he oversaw their immunology discovery research program. John’s clinical and research experience includes appointments at Massachusetts General Hospital, the Dana-Farber Cancer Institute, University of Michigan Medical School, The Scripps Research Institute and Stanford University School of Medicine. He currently serves on the board of directors of Pliant Therapeutics.

John holds an A.B. in biochemistry and molecular biology from Harvard University and an M.D. and Ph.D. in biological chemistry from Harvard Medical School.

Marc currently serves as chief financial officer at AstraZeneca. As a member of the senior executive team at AstraZeneca, Marc is responsible for managing the group’s financing strategy and governance. Marc joined AstraZeneca from GlaxoSmithKline (GSK) in 2013 as executive vice president of global portfolio and product strategy. At GSK, Marc served on the company’s corporate executive team and held positions as president for Asia-Pacific and Japan and foundational global head of GSK’s rare diseases unit. Marc has previously held international positions in operations and general management at Hoechst Marion Roussel.

Marc earned his MBA from the Hautes Etudes Commerciales and a bachelor of law degree from Paris University.

Bobby is a world-renowned scientist and physician and accomplished strategic and organizational leader with more than 25 years of experience in medicine and biotechnology. As one of Orchard’s principal scientific founders, Bobby serves as chief executive officer of the company, and also sits on Orchard’s board of directors. Bobby has been a pioneer in gene therapy and the evolution of hematopoietic stem cell (HSC) technology – including some of the first studies in patients with severe combined immunodeficiency (SCID) – bringing it from some of the first studies in patients to potential regulatory approvals. His unparalleled expertise and deep relationships with key physicians and treatment centers around the world are integral to Orchard’s efforts to identify patients with metachromatic leukodystrophy (MLD) and other diseases through targeted disease education, early diagnosis and comprehensive newborn screening.

Bobby is a professor of pediatrics and immunology at the UCL Great Ormond Street Institute of Child Health and has led multiple clinical trials that have shown that gene therapy can successfully correct the genetic defect in immune deficiencies. He studied medicine and surgery at Kings College in London before completing his Ph.D. at the UCL Institute of Child Health.

Bobby studied medicine and surgery at Kings College in London before completing his Ph.D. at the UCL Institute of Child Health.

Jim is an industry leader with over 30 years of strategic and leadership experience, including more than 20 years as a senior member of executive teams at biotech companies developing and commercializing innovative therapies. Most recently, Jim was an entrepreneur-in-residence at Third Rock Ventures, a leading biotech venture and company formation fund. He previously served as senior vice president, North America strategy and business development at Sanofi, which he joined upon its acquisition of Genzyme. Jim spent over 20 years at Genzyme, where his roles included senior vice president of international development, president of Genzyme Europe and founding president and CEO of Genzyme Transgenics. Jim is chairman of the board for Idera Pharmaceuticals and Pieris Pharmaceuticals, and he also serves on the boards of Voyager Therapeutics and Fulcrum Therapeutics. He started his career in healthcare strategy consulting at Bain.

A graduate of Yale Law School, Jim also holds an M.S. from the University of Pennsylvania and a B.A. from Georgetown University.

Charles is a strategic advisor and board member for multiple biotech companies including Orchard Therapeutics, where he brings more than 30 years of biopharmaceutical industry experience. Charles was most recently the president and chief executive officer of Aurinia Pharmaceuticals, a clinical-stage pharmaceutical company focused on the global lupus nephritis market. Prior to Aurinia, he served as vice president and chief financial officer of ViroPharma, during which time the company grew into a global biopharmaceutical rare diseases business before being acquired by Shire plc. Charles has held finance, operational and executive positions at Endo, Biovail Pharmaceuticals, Breakaway Technologies, Pharmacia, Novartis and Bristol-Myers Squibb, and serves as a member of the board of directors for Blueprint Medicines, Nabriva Therapeutics, Viking Therapeutics and Generation Bio.

Charles holds an MBA from Rutgers University and a B.S. from Saint Joseph’s University.

Alicia has more than 25 years of life sciences leadership and commercial product expertise, with a particular focus in rare disease and other areas of unmet need. Alicia currently serves as president and chief executive officer of Atalanta Therapeutics, a biotechnology company pioneering new treatment options for neurodegenerative diseases. Prior to Atalanta, Alicia served as president and chief executive officer at Juniper Pharmaceuticals, a diversified public healthcare company, where she led the successful turnaround strategy for the company resulting in a sale to Catalent in August 2018. Prior to her role at Juniper, Alicia held a number of leadership positions in the life sciences industry, including chief commercial officer at Zafgen, senior vice president and chief operating officer at Synageva BioPharma, and roles of increasing responsibility at Genzyme, including serving as vice president and general manager of the metabolic disease division, a business with multiple commercial products, including two orphan drugs. Alicia is also a member of the board of directors at GW Pharmaceuticals and the Foundation for Prader-Willi Research.

Alicia received her B.S. in health administration from the University of New Hampshire and an MBA from Northeastern University.